[go: up one dir, main page]

MXPA03010631A - Composicion inmunogenica peptida. - Google Patents

Composicion inmunogenica peptida.

Info

Publication number
MXPA03010631A
MXPA03010631A MXPA03010631A MXPA03010631A MXPA03010631A MX PA03010631 A MXPA03010631 A MX PA03010631A MX PA03010631 A MXPA03010631 A MX PA03010631A MX PA03010631 A MXPA03010631 A MX PA03010631A MX PA03010631 A MXPA03010631 A MX PA03010631A
Authority
MX
Mexico
Prior art keywords
peptide
alzheimer
disease
prevention
treatment
Prior art date
Application number
MXPA03010631A
Other languages
English (en)
Inventor
Yi Wang Chang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of MXPA03010631A publication Critical patent/MXPA03010631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a una composicion que comprende un peptido inmunogeno util para la prevencion y tratamiento de la enfermedad de Alzheimer. Mas particularmente, el peptido inmunogeno comprende un sitio principal funcional/regulador, un fragmento N-terminal del peptido Amiloide ?? (A??) unido al epitope de la celula T auxiliar (Th) que tiene multiples motivos de enlace MHC de clase II. El peptido inmunogeno produce una respuesta inmune dirigida en sitio en contra del sitio regulador/funcional principal del peptido A?? y genera anticuerpos, que son altamente reactivos en forma cruzada para el peptido A??1-42 soluble y las placas amiloides formadas en el cerebro de los pacientes con Enfermedad de Alzheimer. Los anticuerpos producidos siendo reactivos en forma cruzada para el peptido A??1-42 soluble promueven la disgregacion fibril e inhiben la agregacion fibrilar que conduce a la inmunoneutralizacion de las "toxinas A??-derivadas solubles" y siendo reactivas en forma cruzada para las placas amiloides, acelera el despeje de estas placas del cerebro. Ademas, la composicion de la invencion comprende el peptido inmunogeno que es util para la prevencion y el tratamiento de la Enfermedad de Alzheimer.
MXPA03010631A 2001-05-25 2002-04-02 Composicion inmunogenica peptida. MXPA03010631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/865,294 US6906169B2 (en) 2001-05-25 2001-05-25 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
PCT/US2002/010293 WO2002096350A2 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MXPA03010631A true MXPA03010631A (es) 2004-09-13

Family

ID=25345158

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010631A MXPA03010631A (es) 2001-05-25 2002-04-02 Composicion inmunogenica peptida.

Country Status (15)

Country Link
US (3) US6906169B2 (es)
EP (2) EP2123671B1 (es)
JP (3) JP4440544B2 (es)
CN (2) CN1568329B (es)
AT (2) ATE474000T1 (es)
AU (2) AU2002303211B2 (es)
BR (1) BRPI0210010B8 (es)
CA (2) CA2665748C (es)
DE (2) DE60239093D1 (es)
DK (2) DK2123671T3 (es)
ES (2) ES2348975T3 (es)
MX (1) MXPA03010631A (es)
TW (1) TWI252233B (es)
WO (1) WO2002096350A2 (es)
ZA (1) ZA200308767B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US20030086938A1 (en) * 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
CA2400838C (en) * 2000-02-21 2013-04-23 Pharmexa A/S Novel method for down-regulation of amyloid
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2002357007A1 (en) * 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040001848A1 (en) * 2002-03-01 2004-01-01 Szu-Yi Chou Method of producing disease-specific antigens
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2330113B1 (en) * 2002-04-19 2016-06-29 The Governing Council Of The University Of Toronto Immunological methods and compositions for the treatment of Alzheimer's disease
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
EP1515158B1 (en) * 2003-09-09 2013-07-17 Esaote S.p.A. Ultrasound imaging method combined with the presence of contrast media in the body under examination
PH12011502391A1 (en) 2003-12-17 2014-04-28 Janssen Alzheimer Immunotherap A㟠immunogenic peptide carrier conjugates and methods of producing same
US20070172496A1 (en) * 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
PE20061329A1 (es) * 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
NO346055B1 (no) * 2005-12-12 2022-01-24 Ac Immune Sa Antigen konstruksjon, vaksinesammensetning og fremgangsmåte for produksjon derav.
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
CN101421299A (zh) 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
EP2035448A4 (en) 2006-06-01 2010-11-03 Elan Pharm Inc NEUROACTIVE FRAGMENTS OF APP
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
EP2149584B1 (en) 2007-04-20 2017-12-13 The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
US20110256172A1 (en) * 2008-10-14 2011-10-20 The Regents Of The University Of Michigan Epitope-targeted anthrax vaccine
KR101640147B1 (ko) * 2008-10-16 2016-07-18 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 변성된 아밀로이드 베타 펩티드
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US20110221240A1 (en) * 2010-03-11 2011-09-15 Ziming Shen Compact children's table and stool set
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
KR101675185B1 (ko) 2010-07-08 2016-11-10 유나이티드 바이오메디칼 인크. 디자이너(designer) 펩티드-기반 pcv2 백신
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN102775478B (zh) * 2012-08-10 2013-06-19 申联生物医药（上海）有限公司 口蹄疫病毒抗原多肽及疫苗
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
TWI609026B (zh) * 2014-03-14 2017-12-21 美國聯合生物醫學公司 抑制與免疫治療阿茲海默型癡呆的胜肽疫苗
CA3067231A1 (en) * 2017-06-16 2018-12-20 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CA3079236A1 (en) * 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
EP3731934A1 (en) * 2017-12-31 2020-11-04 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases
CN112218655A (zh) * 2018-05-04 2021-01-12 Ubi Ip 控股公司 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产
CA3114657A1 (en) * 2018-10-01 2020-04-09 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
BR112021011938A2 (pt) * 2018-12-19 2021-11-09 United Biomedical Inc Epítopos de célula t helper promíscuos artificiais como imunoestimuladores para imunógenos peptídicos sintéticos
AU2019418627A1 (en) * 2018-12-31 2021-07-29 United Neuroscience Limited Peptide immunogens targeting Calcitonin Gene-Related Peptide (CGRP) and formulations thereof for prevention and treatment of migraine
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN110684122B (zh) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 重组Tau表位嵌合多聚体抗原、其制备方法和应用
PH12022553234A1 (en) * 2020-05-19 2024-02-12 Othair Prothena Ltd Multi-epitope vaccine for the treatment of alzheimer`s disease
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
US20240358806A1 (en) * 2021-09-01 2024-10-31 Vaxxinity, Inc. Methods for the prevention and treatment of synucleinopathies
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
CN116063447B (zh) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 用于检测adap自身抗体的抗原多肽及其应用
TW202438516A (zh) * 2023-01-26 2024-10-01 美商瓦辛尼帝股份有限公司 TAU及β類澱粉肽免疫原組合物及相關方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
CA2081482C (en) 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1308461A3 (en) * 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
CA2161445C (en) * 1993-04-27 2009-06-30 Anna Efim Ladd Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) * 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
AU8091694A (en) 1993-10-26 1995-05-22 United Biomedical Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6919075B1 (en) * 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
IL149976A0 (en) * 1999-12-08 2002-12-01 Mindset Biopharmaceuticals Usa Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
BRPI0210010B8 (pt) 2021-05-25
EP2123671B1 (en) 2011-01-26
CN1568329B (zh) 2013-07-17
DK2123671T3 (da) 2011-05-02
EP1497313B1 (en) 2010-07-14
DE60237044D1 (de) 2010-08-26
AU2008202270B2 (en) 2010-06-17
ZA200308767B (en) 2005-09-28
JP5300593B2 (ja) 2013-09-25
TWI252233B (en) 2006-04-01
EP1497313A2 (en) 2005-01-19
US20110070255A1 (en) 2011-03-24
AU2008202270A1 (en) 2008-06-12
CN1568329A (zh) 2005-01-19
EP2123671A1 (en) 2009-11-25
HK1068215A1 (en) 2005-04-22
ES2348975T3 (es) 2010-12-20
ATE474000T1 (de) 2010-07-15
JP5300592B2 (ja) 2013-09-25
CA2665748A1 (en) 2002-12-05
WO2002096350A3 (en) 2004-11-11
JP2009221213A (ja) 2009-10-01
JP2005506311A (ja) 2005-03-03
JP2009227683A (ja) 2009-10-08
WO2002096350A2 (en) 2002-12-05
ATE496937T1 (de) 2011-02-15
US20030068325A1 (en) 2003-04-10
ES2360465T3 (es) 2011-06-06
BR0210010A (pt) 2005-10-25
CA2448171A1 (en) 2002-12-05
US7951909B2 (en) 2011-05-31
US6906169B2 (en) 2005-06-14
DK1497313T3 (da) 2010-10-25
CN101372511A (zh) 2009-02-25
HK1127898A1 (en) 2009-10-09
JP4440544B2 (ja) 2010-03-24
US8232373B2 (en) 2012-07-31
AU2002303211B2 (en) 2008-02-28
CA2665748C (en) 2014-01-21
BRPI0210010B1 (pt) 2018-03-20
DE60239093D1 (de) 2011-03-10
US20040247612A1 (en) 2004-12-09
EP1497313A4 (en) 2005-11-16
CN101372511B (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
MXPA03010631A (es) Composicion inmunogenica peptida.
BG66083B1 (bg) Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване
AU2006326283B2 (en) Therapeutic vaccine
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MY134906A (en) Prevention and treatment of amyloidogenic disease
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
ZA200708635B (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimers disease
NZ314058A (en) Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
MXPA02008616A (es) Vacuna para el tratamiento de la arterosclerosis.
JP2009520758A5 (es)
WO2003020765A3 (en) Vaccine therapies and prophylactic treatments of atherosclerotic diseases
JP2012526059A (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
LT2002051A (en) Mimetic peptides for epitope of apoliprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
JPH03175983A (ja) ヒトトリプターゼ様蛋白
RU2353389C2 (ru) Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций
WO2002102849A3 (en) Bcmp-101, a cancer associated protein

Legal Events

Date Code Title Description
FG Grant or registration